Impax Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Impax Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$19.9M	Sell	154,303 -125,453	-45%	-$14M	1.18%	19
2018 Q1	$28.8M	Sell	279,756 -1,603	-0.6%	-$159K	1.66%	6
2017 Q4	$24M	Sell	281,359 -11,092	-4%	-$961K	1.38%	14
2017 Q3	$24.8M	Hold	292,451	–	–	1.42%	13
2017 Q2	$22.1M	Buy	292,451 +16,573	+6%	+$1.16M	1.25%	24
2017 Q1	$18.2M	Buy	275,878 +46,570	+20%	+$3.06M	1.02%	35
2016 Q4	$14.5M	Buy	229,308 +27,251	+13%	+$1.72M	0.83%	57
2016 Q3	$12.9M	Buy	202,057 +121,907	+152%	+$8.95M	0.74%	63
2016 Q2	$5.96M	Buy	80,150 +24,382	+44%	+$1.81M	0.35%	98
2016 Q1	$3.73M	Buy	+55,768	New	+$3.39M	0.2%	116
2014 Q3	–	Sell	-74,102	Closed	-$2.88M	–	193
2014 Q2	$2.88M	Buy	+74,102	New	+$3.01M	0.18%	101

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Impax Asset Management's LGND Position: Q2 2018 in Review

Impax Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 45% in Q2 2018, selling an estimated $14M and leaving 154,303 shares worth $19.9M. The position accounts for 1.18% of the portfolio, ranked #19.

Impax Asset Management first reported a position in LGND in Q2 2014 and has held it in 11 quarters since. The position peaked at $28.8M in Q1 2018. 346 funds tracked by Wall St. Rank hold LGND as of Q2 2018.

Impax Asset Management held 154,303 shares of Ligand Pharmaceuticals worth $19.9M as of Q2 2018.
Impax Asset Management sold 125,453 Ligand Pharmaceuticals shares in Q2 2018, an estimated $14M.
Ligand Pharmaceuticals made up 1.18% of Impax Asset Management's portfolio in Q2 2018, its #19 holding.
Impax Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
Impax Asset Management's Ligand Pharmaceuticals position peaked at $28.8M in Q1 2018.
346 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2018.

Based on Impax Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.